In October 2020 the European Medicines Agency (EMA) expressed positive opinion on the adoption and extension of indication for a number of treatments addressed to the paediatric population. This is the case of Dupixent (dupilumab), for which on 15 October 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted an extension to the
The European Paediatric Formulation Initiative (EuPFI) works to improve the preparation of better and safer medicines for children. One area they are interested in is the “gadgets” or devices (e.g. measuring spoons, dosing cups, inhalers) that are used to help patients take their medicines. It is important that these devices are used properly to make
The first General Assembly of the EPTRI (European Paediatric Translational Research Infrastructure) Italian Node (EPTRI-IT) was held online on October 28th, 2020. The 3 hours meeting was attended by more than 60 representatives coming from the 24 Italian Institutions – members of the Node. TEDDY is pleased to announce its involvement in EPTRI-IT that will
On 31 August 2020, the Enpr-EMA (European Network of Paediatric Research at the European Medicines Agency) working group on trial preparedness published recommendations on preparedness of medicines’ clinical trials in paediatrics. Enpr-EMA held a two-month public consultation on the draft document from September 2019 until November 2019, with the aim of identifying potential gaps and
On 25 November 2020, the European Commission published the inception impact assessment on the revision of the Orphan and Paediatric Regulation. EU legislation on medicines for children and rare diseases was introduced in the early 2000’s, to address the lack of medicines in this area. Now, the revision of the Regulations will be open for
The TEDDY Chair, Annagrazia Altavilla, consultant and expert of the Council of Europe, is very pleased to announce the approval by the Committee on Bioethics of Council of Europe of a Concept note on “Participation of children in the decision-making process on matters regarding their health”. It constitutes an important step in drawing the pathway
On 31 August 2020, the Enpr-EMA (European Network of Paediatric Research at the European Medicines Agency) working group on trial preparedness published recommendations on preparedness of medicines’ clinical trials in paediatrics. Enpr-EMA held a two-month public consultation on the draft document from September 2019 until November 2019, with the aim of identifying potential gaps and
EMA has recommended granting a marketing authorisation in the European Union for the gene therapy Libmeldy to treat metachromatic leukodystrophy (MLD), a rare inherited metabolic disease that affects the nervous system. Libmeldy is indicated for use in children with the ‘late infantile’ or ‘early juvenile’ forms of MLD, who have been identified as carriers of
On 30 November 2020, the European Medicines Agency will organise a workshop on support for orphan medicines development with the aim to encourage early and efficient interactions with the regulators by highlighting pre-marketing support in medicine development in rare diseases. Existing tools such as orphan designation, protocol assistance and PRIME scheme will be highlighted and
On November 30 until December 6, 2020, the Duchenne Data Foundation has organised its third Edition of the “Duchenne Patient Academy”. The Duchenne Patient Academy has the aim to create a wider understanding of Duchenne Muscular Dystrophy (DMD) and coordinate the global advocacy of the community. Due to pandemic, this year the event will be